Previous 10 | Next 10 |
Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...
-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeut...
Celldex (CLDX): Q3 GAAP EPS of -$0.36 in-line.Revenue of $0.67M (+21.8% Y/Y) beats by $0.27M.Cash, cash equivalents and marketable securities of $199.6M. Press Release For further details see: Celldex EPS in-line, beats on revenue
HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the third quarter, building on the compelling CDX-0159 data presented at EAACI, we init...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...
Celldex Therapeutics (CLDX) has dosed the first patient in its Phase 1b study of CDX-0159 for chronic spontaneous urticaria ((CSU)). Hives (urticaria) are red, itchy welts that result from a skin reaction. The condition is considered chronic hives if the welts appear for more than six we...
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU). CDX-0159...
With huge investments being made in the biotech industry thanks to the pandemic, it’s an opportune time to consider investing in the industry, Here are four stocks worth a look: Amgen (AMGN), Immunomedics (IMMU), Trevena (TRVN), abd Celldex Therapeutics (CLDX). Biotechnology has be...
Celldex stock rose sharply after CDX-0159 data was announced in June. CDX-527 Phase 1 trial is now underway. Topline CD-3379 Phase 2 data should arrive before year-end. For further details see: Why Celldex Has Been A Big Winner In 2020
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...